Reply to B. Kurland et al.
Franck Bonnetain, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit; and The French National Platform Quality of Life and Cancer; Institut National de la Santé et de la Recherche Médicale UMR 1098, Besançon France; Fabio Efficace, Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases, Rome, Italy; Frédéric Fiteni, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit, Besançon, France; and Amélie Anota, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit; and The French National Platform Quality of Life and Cancer; Institut National de la Santé et de la Recherche Médicale UMR 1098, Besançon, France.
Franck
F
Bonnetain
Franck Bonnetain, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit; and The French National Platform Quality of Life and Cancer; Institut National de la Santé et de la Recherche Médicale UMR 1098, Besançon France; Fabio Efficace, Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases, Rome, Italy; Frédéric Fiteni, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit, Besançon, France; and Amélie Anota, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit; and The French National Platform Quality of Life and Cancer; Institut National de la Santé et de la Recherche Médicale UMR 1098, Besançon, France.
Fabio
F
Efficace
Franck Bonnetain, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit; and The French National Platform Quality of Life and Cancer; Institut National de la Santé et de la Recherche Médicale UMR 1098, Besançon France; Fabio Efficace, Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases, Rome, Italy; Frédéric Fiteni, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit, Besançon, France; and Amélie Anota, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit; and The French National Platform Quality of Life and Cancer; Institut National de la Santé et de la Recherche Médicale UMR 1098, Besançon, France.
Frédéric
F
Fiteni
Franck Bonnetain, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit; and The French National Platform Quality of Life and Cancer; Institut National de la Santé et de la Recherche Médicale UMR 1098, Besançon France; Fabio Efficace, Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases, Rome, Italy; Frédéric Fiteni, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit, Besançon, France; and Amélie Anota, University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit; and The French National Platform Quality of Life and Cancer; Institut National de la Santé et de la Recherche Médicale UMR 1098, Besançon, France.
Amélie
A
Anota
D006801:Humans; D011471:Prostatic Neoplasms